DE69927829D1 - Zelltyp specifischer gentransfer der retroviralen vektoren die antikörper-hüllen fusionsproteine und wildtyp-hüllen fusionsproteine enthalten - Google Patents

Zelltyp specifischer gentransfer der retroviralen vektoren die antikörper-hüllen fusionsproteine und wildtyp-hüllen fusionsproteine enthalten

Info

Publication number
DE69927829D1
DE69927829D1 DE69927829T DE69927829T DE69927829D1 DE 69927829 D1 DE69927829 D1 DE 69927829D1 DE 69927829 T DE69927829 T DE 69927829T DE 69927829 T DE69927829 T DE 69927829T DE 69927829 D1 DE69927829 D1 DE 69927829D1
Authority
DE
Germany
Prior art keywords
fusion proteins
covers
gentransfer
covers fusion
vectors containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69927829T
Other languages
English (en)
Other versions
DE69927829T2 (de
Inventor
Ralph C Dornburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of DE69927829D1 publication Critical patent/DE69927829D1/de
Application granted granted Critical
Publication of DE69927829T2 publication Critical patent/DE69927829T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69927829T 1998-08-17 1999-08-10 Zelltyp spezifischer gentransfer der retroviralen vektoren die antikörper-hüllen fusionsproteine und wildtyp-hüllen fusionsproteine enthalten Expired - Fee Related DE69927829T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US135121 1998-08-17
US09/135,121 US6534051B1 (en) 1992-11-20 1998-08-17 Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
PCT/US1999/018141 WO2000009730A2 (en) 1998-08-17 1999-08-10 Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins

Publications (2)

Publication Number Publication Date
DE69927829D1 true DE69927829D1 (de) 2006-03-02
DE69927829T2 DE69927829T2 (de) 2006-07-06

Family

ID=22466650

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69927829T Expired - Fee Related DE69927829T2 (de) 1998-08-17 1999-08-10 Zelltyp spezifischer gentransfer der retroviralen vektoren die antikörper-hüllen fusionsproteine und wildtyp-hüllen fusionsproteine enthalten

Country Status (6)

Country Link
US (2) US6534051B1 (de)
EP (1) EP1104482B1 (de)
JP (1) JP2002522090A (de)
AU (1) AU5396399A (de)
DE (1) DE69927829T2 (de)
WO (1) WO2000009730A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
IT1290428B1 (it) * 1997-03-21 1998-12-03 Ausimont Spa Grassi fluorurati
JP2002532066A (ja) 1998-11-16 2002-10-02 ジェンウェイ バイオテック， インコーポレイテッド 鳥類におけるポリヌクレオチドワクチンを用いる抗体の産生
US7348014B2 (en) 2000-04-14 2008-03-25 Transgene, S.A. Poxvirus with targeted infection specificity
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
EP1444989A1 (de) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
DE10361167A1 (de) * 2003-12-22 2005-07-28 Brand Gmbh + Co Kg Verpackungsbox für Laborgegenstände
EP2963118B1 (de) 2005-06-01 2017-08-09 California Institute of Technology Verfahren zur gezielten genabgabe über virale vektoren
CN101529253A (zh) * 2006-06-21 2009-09-09 阿珀吉尼科斯有限公司 Il-4和/或il-10细胞因子在人癌症中的差异表达
AU2007271349A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
KR101421312B1 (ko) 2006-07-21 2014-07-31 캘리포니아 인스티튜트 오브 테크놀로지 수지상 세포 백신접종을 위한 표적화된 유전자의 전달
MX347291B (es) * 2009-03-20 2017-04-17 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
SI2456786T2 (sl) 2009-07-24 2017-08-31 Immune Design Corp. Lentiviralni vektorji psevdo-tipizirani z glikoproteinom ovojnice virusa Sindbis
EA201370076A1 (ru) 2010-09-22 2013-08-30 Амген Инк. Иммуноглобулины-переносчики и их применение
DK2831095T3 (en) 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
JP7178701B2 (ja) * 2017-01-19 2022-11-28 国立大学法人 東京大学 新規蛍光標識方法
US20200215112A1 (en) * 2017-08-09 2020-07-09 Ctg Pharma Ltd. Chimeric antigen receptor for her2/neu and t-cells expressing same
AU2019378883A1 (en) * 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for T cell delivery
US20210396703A1 (en) * 2020-06-17 2021-12-23 Northeastern University Rapid Electrochemical Point-of-Care COVID-19 Detection in Human Saliva

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
WO1990012087A1 (en) 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
EP1285967A3 (de) 1990-09-21 2005-03-02 Chiron Corporation Humanische Retroviren- Packaging Zellinie
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
WO1993000103A1 (en) 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
JPH08504091A (ja) 1992-09-22 1996-05-07 メディカル・リサーチ・カウンシル 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス
EP0672129A4 (de) 1992-11-20 1997-06-11 Univ New Jersey Med Zelltyp spezifischer gentransfer mit hilfe von retroviralen vektoren welche antikörper-hülle fusionsproteine haben.
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5869331A (en) * 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
CA2184354A1 (en) 1994-03-04 1995-09-08 Ralph C. Dornburg Cell-type specific gene transfer using retroviral vectors containing antibody-envelope and wild-type envelope-fusion proteins

Also Published As

Publication number Publication date
EP1104482A2 (de) 2001-06-06
AU5396399A (en) 2000-03-06
EP1104482B1 (de) 2005-10-19
WO2000009730A2 (en) 2000-02-24
US6534051B1 (en) 2003-03-18
JP2002522090A (ja) 2002-07-23
US20030017140A1 (en) 2003-01-23
WO2000009730A3 (en) 2000-05-18
DE69927829T2 (de) 2006-07-06

Similar Documents

Publication Publication Date Title
DE69927829D1 (de) Zelltyp specifischer gentransfer der retroviralen vektoren die antikörper-hüllen fusionsproteine und wildtyp-hüllen fusionsproteine enthalten
DE69432788D1 (de) Elektrolytloesung und daraus hergestelltes elektrochemisches element
ID19961A (id) Sel jenis tipis
DE69715799D1 (de) Ionisch leitfähige Materialien, die eine von Malononitril abgeleitete ionische Verbindung enthalten und ihre Verwendungen
DE69419786T2 (de) Elektrochemische Überwachung von Behälter-Durchlässigkeiten
DE69633239D1 (de) Trockenes festes medium zur lagerung und analyse von genetischem material
DE69638282D1 (de) Trockenes festes Medium zur Aufbewahrung und Analyse von genetischem Material
EP1007949A4 (de) Mehrfache proben von zellproben
DE69634670D1 (de) Aktives anodenmaterial und nichtwässrige sekundärbatterie
BR9406754A (pt) Eletrólito sólido composito e bateria
BR9508429A (pt) Célula de bateria e bateria
DE69505257D1 (de) Elektrochemische oxydation von materialien
DE69841509D1 (de) Lektrodenfomstück und elektrochemische elemente
DE59800980D1 (de) Mischungen von Reaktivfarbstoffen und deren Verwendung
ID25722A (id) Penganalisa partikel-partikel padat terlarut
DE69841343D1 (de) Festelektrolytzelle
NO169265C (no) Kretsanordning for modifisering av dynamikkomraade ved benyttelse av virkningserstatnings- og overlagringsteknikker.
FI961072A0 (fi) Kiinteän olomuodon sähkökemiallinen kenno
DE59510541D1 (de) Elektrochemische Zelle
DE69701232D1 (de) Ternäre feste Lösungen von 1,4-Diketopyrrolopyrrolen und Chinacridonen
BR8602998A (pt) Eletrolito ternario e celula de estado solido
DE69603513T2 (de) Gelartig festgelegter Elektrolyt und diesen enthaltende Zelle
DE69435098D1 (de) Neuartige polypeptide und dafür kodierende dna
IT1171841B (it) 1,3-diammino-4-(2',2',27-trifluoroetossi)-benzolo, procedimento per la sua produzione e tinture per capelli che lo contengono
DE69425707T2 (de) Medien für die isolierung und stabilisierung von zellen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee